191 related articles for article (PubMed ID: 9048270)
1. Bioavailability of sublingual buprenorphine.
Mendelson J; Upton RA; Everhart ET; Jacob P; Jones RT
J Clin Pharmacol; 1997 Jan; 37(1):31-7. PubMed ID: 9048270
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations.
Nath RP; Upton RA; Everhart ET; Cheung P; Shwonek P; Jones RT; Mendelson JE
J Clin Pharmacol; 1999 Jun; 39(6):619-23. PubMed ID: 10354966
[TBL] [Abstract][Full Text] [Related]
3. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
Lim SCB; Schug S; Krishnarajah J
Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
[TBL] [Abstract][Full Text] [Related]
4. Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine.
Everhart ET; Cheung P; Shwonek P; Zabel K; Tisdale EC; Jacob P; Mendelson J; Jones RT
Clin Chem; 1997 Dec; 43(12):2292-302. PubMed ID: 9439446
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet.
Schuh KJ; Johanson CE
Drug Alcohol Depend; 1999 Aug; 56(1):55-60. PubMed ID: 10462093
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
Jönsson M; Mundin G; Sumner M
Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
[TBL] [Abstract][Full Text] [Related]
7. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
[TBL] [Abstract][Full Text] [Related]
10. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
Kuhlman JJ; Lalani S; Magluilo J; Levine B; Darwin WD
J Anal Toxicol; 1996 Oct; 20(6):369-78. PubMed ID: 8889672
[TBL] [Abstract][Full Text] [Related]
11. Sublingual absorption of selected opioid analgesics.
Weinberg DS; Inturrisi CE; Reidenberg B; Moulin DE; Nip TJ; Wallenstein S; Houde RW; Foley KM
Clin Pharmacol Ther; 1988 Sep; 44(3):335-42. PubMed ID: 2458208
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM
Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606
[TBL] [Abstract][Full Text] [Related]
13. Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site.
Messenger KM; Davis JL; LaFevers DH; Barlow BM; Posner LP
Vet Anaesth Analg; 2011 Jul; 38(4):374-84. PubMed ID: 21501371
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals.
Grubb TL; Kurkowski D; Sellon DC; Seino KK; Coffey T; Davis JL
J Vet Pharmacol Ther; 2019 Jan; 42(1):26-36. PubMed ID: 30242851
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
16. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
Bai SA; Xiang Q; Finn A
Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639
[TBL] [Abstract][Full Text] [Related]
18. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.
Bastian JR; Chen H; Zhang H; Rothenberger S; Tarter R; English D; Venkataramanan R; Caritis SN
Am J Obstet Gynecol; 2017 Jan; 216(1):64.e1-64.e7. PubMed ID: 27687214
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
Compton P; Ling W; Moody D; Chiang N
Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
